两票制下,制药企业和商业企业怎么合作?

2017-05-05 医药史立臣 两票制下,制药企业和商业企业怎么合作?

原来的制药企业工作重心是产品生产和研发,以及品牌建设,工商一体化后,制药企业还要做仓储、物流等商业工作。

现在,由于两票制实施,很多商业企业面临难以为继的情况,但是,一些商业企业自身承接着一些大型制药企业的区域销售功能,但有没有终端资源和能力承接两票制中的最后一票,这对大型制药企业来说,是个两难的选择。麦斯康莱行业专家从各地执行两票制的规定中可以梳理出两个亮点:1.三种情形视同生产企业(1)药品耗材生产企业或科工贸一体化的集团型企业设立的仅销售本企业(集团)耗材的全资或控股商业公司;(2)境外药品耗材国内总代办(仅限1家);(3)委托生产企业或经营企业代为销售的药品耗材上市许可持有人。2. 国内流通集团型企业内部像全资或控股子公司调拨药品可不视为一票,但是最多只允许开一次发票。(四川)可见,上述两点尤其是第一点让很多大型制药企业心动,就是科工贸一体化的商业公司算作一票。于是很多制药企业开始兼并与自身业务多年合作的商业企业,使之成为自身的区域销售公司。工商一体化的营销模式,说简单了就是制药企业延伸到渠道层面,通过区域的商业企业覆盖下游渠道和终端。原来的制药企业工作重心是产品生产和研发,以及品牌建设,工商一体化后,制药企业还要做仓储、物流等商业工作。通过工商一体化,可以在新的政策形势下构建营销

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1771734, encodeId=b34f1e717349f, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Sat Dec 02 18:45:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419535, encodeId=4c32141953524, content=<a href='/topic/show?id=447d2109ee4' target=_blank style='color:#2F92EE;'>#两票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21097, encryptionId=447d2109ee4, topicName=两票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1103505700, createdName=天堂的云, createdTime=Sun May 07 01:45:00 CST 2017, time=2017-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456072, encodeId=32a714560e2e9, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun May 07 01:45:00 CST 2017, time=2017-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596322, encodeId=5a0f1596322fc, content=<a href='/topic/show?id=31693238980' target=_blank style='color:#2F92EE;'>#制药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32389, encryptionId=31693238980, topicName=制药企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2c818366159, createdName=listen324, createdTime=Sun May 07 01:45:00 CST 2017, time=2017-05-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1771734, encodeId=b34f1e717349f, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Sat Dec 02 18:45:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419535, encodeId=4c32141953524, content=<a href='/topic/show?id=447d2109ee4' target=_blank style='color:#2F92EE;'>#两票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21097, encryptionId=447d2109ee4, topicName=两票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1103505700, createdName=天堂的云, createdTime=Sun May 07 01:45:00 CST 2017, time=2017-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456072, encodeId=32a714560e2e9, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun May 07 01:45:00 CST 2017, time=2017-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596322, encodeId=5a0f1596322fc, content=<a href='/topic/show?id=31693238980' target=_blank style='color:#2F92EE;'>#制药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32389, encryptionId=31693238980, topicName=制药企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2c818366159, createdName=listen324, createdTime=Sun May 07 01:45:00 CST 2017, time=2017-05-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1771734, encodeId=b34f1e717349f, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Sat Dec 02 18:45:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419535, encodeId=4c32141953524, content=<a href='/topic/show?id=447d2109ee4' target=_blank style='color:#2F92EE;'>#两票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21097, encryptionId=447d2109ee4, topicName=两票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1103505700, createdName=天堂的云, createdTime=Sun May 07 01:45:00 CST 2017, time=2017-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456072, encodeId=32a714560e2e9, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun May 07 01:45:00 CST 2017, time=2017-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596322, encodeId=5a0f1596322fc, content=<a href='/topic/show?id=31693238980' target=_blank style='color:#2F92EE;'>#制药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32389, encryptionId=31693238980, topicName=制药企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2c818366159, createdName=listen324, createdTime=Sun May 07 01:45:00 CST 2017, time=2017-05-07, status=1, ipAttribution=)]
    2017-05-07 hyf030
  4. [GetPortalCommentsPageByObjectIdResponse(id=1771734, encodeId=b34f1e717349f, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Sat Dec 02 18:45:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419535, encodeId=4c32141953524, content=<a href='/topic/show?id=447d2109ee4' target=_blank style='color:#2F92EE;'>#两票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21097, encryptionId=447d2109ee4, topicName=两票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1103505700, createdName=天堂的云, createdTime=Sun May 07 01:45:00 CST 2017, time=2017-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456072, encodeId=32a714560e2e9, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun May 07 01:45:00 CST 2017, time=2017-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596322, encodeId=5a0f1596322fc, content=<a href='/topic/show?id=31693238980' target=_blank style='color:#2F92EE;'>#制药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32389, encryptionId=31693238980, topicName=制药企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2c818366159, createdName=listen324, createdTime=Sun May 07 01:45:00 CST 2017, time=2017-05-07, status=1, ipAttribution=)]

相关资讯

医药行业新的商业机会在哪里?

一个行业,持续时间久了,就会形成一定的思维惯性

营销变革,就是现在!

制药企业新营销组织,核心就是要构建体系化的组织形态,这样,即便是人来人往,体系的力量也会让制药企业的营销具有持续的可能性。

山东发布《规划》:要打造健康山东重视慢性病

近日,山东省人民政府正式发布《山东省“十三五”卫生与健康规划》,全文内容共约1万9千字,先后15次提到慢性病、4次提到健康山东,具体内容笔者为您详细整理、重点解读......

医药商业企业四大转型方向(下篇)

在国家的政策导向下,我国的医药商业各种要素会进行碎片化分解,随着分解,各种商业要素会向专业化方向发展。

医药商业企业四大转型方向(上篇)

国家的政策导向下,我国的医药商业各种要素会进行碎片化分解,随着分解,各种商业要素会向专业化方向发展。

现代阿Q

我有一个朋友,我叫他阿Q。